Efficacy of risankizumab across subgroups in patients with active psoriatic arthritis: a post hoc integrated analysis of the phase 3 KEEPsAKE 1 and KEEPsAKE 2 randomized controlled trials

By sjmartinez • April 18, 2024

Merola JF, Armstrong A, Khattri S, Paek SY, Padilla B, Yue C, Photowala H, Kaplan B, Kristensen LE. Efficacy of risankizumab across subgroups in patients with active psoriatic arthritis: a post hoc integrated analysis of the phase 3 KEEPsAKE 1 and KEEPsAKE 2 randomized controlled trials. J Dermatolog Treat. 2024 Dec;35(1):2342383. doi: 10.1080/09546634.2024.2342383. Epub 2024 Apr 18. PMID: 38632977.

Tags: Biologics, Dermatology, interleukin-23, psoriatic arthritis, Publications, risankizumab

Related Posts

Efficacy and safety of rocatinlimab for the treatment of moderate-to-severe atopic dermatitis in ROCKET-IGNITE and ROCKET-HORIZON: two global, double-blind, placebo-controlled, randomised phase 3 clinical trials

Guttman-Yassky E, Kabashima K, Worm M, Luna PC, Hong HC, Chovatiya R, Bernstein JA, Kern JS, Ehst BD, Magnolo N, Herranz-Pinto P, Stein Gold L,[...]

A scalp to make you squirm: Cutaneous myiasis hiding a unique presentation of disseminated coccidioidomycosis

Duldulao JM, Modanlo N, Boppana S, Adachi K, Dong HV, Kaur I, Nielsen-Saines K, Terrell J, Cheng CE, Malhotra S. A scalp to make you[...]

Is Cumulative Life Course Impairment Considered in Psoriasis Management? A Multinational Survey of People with Psoriasis and Healthcare Professionals

Matthews R, Armstrong AW, Augustin M, Baker C, Carrascosa JM, Kirby B, Langley R, McBride S, Reich A, Romiti R, Sampogna F, Warren RB. Is[...]